Orexigen Therapeutics to Present Data Supporting Novel, PreClinical Drug Combination for Schizophrenia
SAN DIEGO--(BUSINESS WIRE)--Nov 1, 2007 - Orexigen(TM) Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, today announced that the Company will be presenting at the Society for Neuroscience Annual meeting, Neuroscience 2007, in San Diego, CA, November 3-7, 2007.Orexigen's Vice President of Neuroscience, Frank Bymaster, will present pre-clinical data on the effect of the combination of zonisamide and ziprasidone on extracellular concentrations of monoamines in the prefrontal cortex and hypothalamus in rats.
Orexigen's poster presentation at Neuroscience 2007 is: -0-
Program #/Poster # : 472.23/N9 Title: Effect of the Combination of Ziprasidone and Zonisamide on Extracellular Concentrations of Monoamines in Rat Prefrontal Cortex and Hypothalamus Location: San Diego Convention Center, Halls B-H Time: Monday, November 5th, 2007, 3:00-4:00pm PST Presenter: Frank Bymaster
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders including obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in Phase III clinical trials, and Empatic(TM), which is in the later stages of Phase II development. Both product candidates are designed to take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.Orexigen.com.
Contact
OREXIGEN
Graham Cooper, 858-436-8600
or
MEDIA
Stephen Gendel, 212-918-4650
or
INVESTORS
Jason Spark, 619-849-6005
